US Stock MarketDetailed Quotes

BFRI Biofrontera

Watchlist
  • 0.7590
  • -0.0209-2.68%
Close Nov 21 16:00 ET
  • 0.7500
  • -0.0090-1.19%
Post 20:01 ET
5.88MMarket Cap0.65P/E (TTM)

About Biofrontera Company

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Company Profile

SymbolBFRI
Company NameBiofrontera
Listing DateOct 29, 2021
Issue Price4.99
Founded2015
CEODr. Hermann Luebbert, PhD
MarketNASDAQ
Employees85
Fiscal Year Ends12-31
Address120 Presidnetial Way,Suite 330
CityWoburn
ProvinceMassachusetts
CountryUnited States of America
Zip Code01801
Phone1-781-245-1325

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Hermann Luebbert, PhD
  • Executive Chairman of the Board and Chief Executive Officer
  • 733.23K
  • Eugene Fredrick Leffler, III
  • Chief Financial Officer and Principal Accounting Officer
  • 441.68K
  • Dr. Heikki Lanckriet, PhD
  • Director
  • 19.36K
  • Kevin D. Weber
  • Independent Director
  • 58.01K
  • John J. Borer, III,J.D.
  • Independent Director
  • 68.64K
  • Dr. Beth J. Hoffman, PhD
  • Independent Director
  • 64.47K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data